Global Microbiome Drugs Market is expected to reach US$ XX Mn by 2026 from US$ XX Mn in 2019, at a CAGR of 15 % during the forecast period.
Global Microbiome Drugs Market Overview:

The Microbiome is being recognised as a central mediator of drug action, as it regulates many aspects of host health and disease. The Microbiomes from the human body are used for disease care. These medications extracted from microbiomes help the physician in making a more accurate diagnosis of the disease.
Global Microbiome Drugs Market Dynamics:

The increasing prevalence of lifestyle disorders drives the global market.

The human microbiome has been linked to lifestyle disorders such as cancer, diabetes, and obesity. Changing lifestyle and social norms have a direct effect on the microbiome. Making the alterations to the human microbiome will aid in the prevention of lifestyle diseases.

According to the World Health Organisation, 13% of the world's adult population was obese in 2016. In terms of minimising the adverse effects induced by the overuse of antibiotics, technological advances done in human microbiome drugs and diagnostics have outperformed traditional approaches.

The growth of this market is being driven by rising cases of chronic diseases such as diabetes, and the ability of drugs to diagnose them at the early stage. Also, increased awareness among people to maintain a healthy lifestyle further boosts the market growth. Other factors such as the growing geriatric population, rise in healthcare expenditure and the demand for successful procedures and safe medications are expected to fuel market growth.

Microbiome therapy has grown in popularity over the last decade. The National Institutes of Health (NIH) spent USD 215 million on the Human Microbiome Project (HMP) and USD 728 million on extramural human microbiome research activities outside of the HMP during the last decade.
Rising pharmaceutical company partnership for the production of novel drugs is another important factor impacting the market growth. The Seres

Therapeutics in the United States and Nestlé Health Science collaborated to develop and commercialise a broad product pipeline for ulcerative colitis and C. difficile infection.

However, in developing regions, lack of knowledge about the health benefits of probiotics and prebiotics, stringent government regulations, is expected to limit the market growth. Along with this, lack of regulatory pathways and delays in the launch of microbiome products are also expected to hamper the market's growth during the forecast period.

The report has profiled seventeen key players in the market from different regions. However, the report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for a future hot spot in APAC region.
Global Microbiome Drugs Market Segment Analysis:

The Global Microbiome Drugs Market is segmented on the basis of Product Type, Application and End-Users.

Based on Product Type, the Probiotics segment accounted for the largest market share in 2019. Due to an increase in the prevalence of health issues, increased understanding of the relationship between nutrition, diet, and health, and increased use of probiotics in the dairy and other foods industry, this segment is expected to dominate the market during the forecast period.

Next-generation probiotics, such as Akkermansia muciniphila, Bacteroides uniformis, Clostridium clusters IV, XIVa, and XVIII, and F. prausnitzii, have been established as a result of microbiome research. With improved clinical results, these new-age probiotics are expected to boost the demand in the coming years. Furthermore, the prebiotics segment is expected to rise at the fastest pace during forecast years.
 
For a more information@:  https://www.maximizemarketresearch.com/market-report/global-microbiome-drugs-market/100909/

Share this ads